Incyte agreed to acquire Vega Therapeutics for up to $2 billion, adding VGA039, a Phase III monoclonal antibody for von Willebrand disease (VWD). Vega039 is designed to modulate Protein S to improve hemostasis, with a goal of once-monthly subcutaneous prophylaxis intended to replace more frequent intravenous infusions. VGA039 is being tested in the Phase III VIVID-6 trial (NCT07115004), a global single-arm crossover design intended to evaluate safety and efficacy across VWD types. Incyte quantified the commercial opportunity as $1B+ in potential net sales. The deal shows how payers and patients are driving a dosing convenience premium in bleeding disorders, while Incyte tries to build growth around its hematology portfolio following Jakafi’s long-term trajectory.